ACP
IOVA icon

Acuta Capital Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Acuta Capital Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-190,000
Closed -$2.43M – 40
2018
Q2 		$2.43M Sell
190,000
-13,300
-7% -$194K 0.43% 36
2018
Q1 		$3.44M Buy
203,300
+192,300
+1,748% +$2.91M 0.56% 26
2017
Q4 		$88K Buy
+11,000
New +$88.3K 0.02% 70
2017
Q3 		– Sell
-324,000
Closed -$2.38M – 72
2017
Q2 		$2.38M Buy
324,000
+284,000
+710% +$1.81M 0.67% 29
2017
Q1 		$298K Sell
40,000
-110,000
-73% -$806K 0.07% 63
2016
Q4 		$1.04M Buy
+150,000
New +$1.03M 0.39% 35

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Acuta Capital Partners's IOVA Position: Q2 2023 in Review

Acuta Capital Partners sold out of Iovance Biotherapeutics (IOVA) in Q2 2023, closing a stake of 153,639 shares — an estimated $939K sold.

Acuta Capital Partners first reported a position in IOVA in Q1 2015 and held it in 33 quarters. The position peaked at $72M in Q1 2018. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.

  • Acuta Capital Partners reported no remaining Iovance Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Acuta Capital Partners sold 153,639 Iovance Biotherapeutics shares in Q2 2023, an estimated $939K.
  • Acuta Capital Partners first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 33 quarters.
  • Acuta Capital Partners's Iovance Biotherapeutics position peaked at $72M in Q1 2018.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.

Based on Acuta Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.